Shares of molecular diagnostics company TrovaGene (NASDAQ:TROV) are collapsing – down nearly 55% as of this writing. The reason?
Shares of biotechnology company TrovaGene Inc (NASDAQ:TROV) are collapsing – down nearly 40% as of this writing. The reason?
Investors are racing to buy TrovaGene Inc (NASDAQ:TROV) shares after the U.S.
Maxim Group analyst Jason Kolbert was out pounding the table on TrovaGene Inc (NASDAQ:TROV) Thursday, reiterating a Buy rating and price target of $13, …
